Please provide your email address to receive an email when new articles are posted on . In patients with recurrent pericarditis, compared with placebo, rilonacept better resolved recurrent episodes ...
ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy Regeneron plans to file by mid-2011 for ...
HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and ...
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of ...
Rilonacept, an interleukin (IL)-1 inhibitor, produces rapid resolution of recurrent pericarditis and fewer recurrent pericarditis episodes among patients who initially respond to drug therapy, as ...
Kiniksa Pharmaceuticals announced positive data from the phase 3 RHAPSODY trial evaluating rilonacept for the treatment of recurrent pericarditis. Kiniksa Pharmaceuticals announced positive data from ...
HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and ...
HAMILTON, Bermuda, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results